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Abstract 
Gabapentin is an anticonvulsant and nerve pain medication with a variety of off-
label indications.  There is at least some evidence that physicians have pre-
scribed gabapentin to successfully treat several off-label conditions including al-
cohol dependence and withdrawal, brachioradial pruritus, chronic, refractory 
cough, diabetic neuropathy, fibromyalgia, hiccups (singultus), hot flashes, insom-
nia, neuropathic pain, adjunct therapy for postoperative pain, restless legs syn-
drome (RLS), anxiety disorders, and uremic pruritus.   
An observational cross-sectional study was used to determine the various real-
life off-label uses of gabapentin and physicians’ perspectives with regard to par-
ticular advantages over other drugs and interventions, via an online survey.  In 
addition, a secondary objective was to determine physicians’ perspectives re-
garding whether gabapentin is being misused.  The most common off-label indi-
cations for prescribing gabapentin for Family Medicine and most other physicians 
surveyed were neuropathic pain, diabetic neuropathy, and fibromyalgia.   Psychi-
atrists most commonly prescribed gabapentin for anxiety disorders and insomnia.  
With respect to misuse and overdose, six Emergency Medicine physicians felt 
that gabapentin was not leading to increased overdoses and/or intoxications 
while three felt that it was. 
Keywords: Gabapentin, Off-label Use, Off-label Indications, Prescribing prac-
tices, Misuse
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Gabapentin is an anticonvulsant medication with a variety of off-label indications.  
The two FDA-approved indications for gabapentin are partial seizures and pos-
therpetic neuralgia.  There is at least some evidence that physicians have pre-
scribed gabapentin to successfully treat several off-label conditions including al-
cohol dependence [4-6] and withdrawal [7], bipolar disorder [8], brachioradial pru-
ritus [9-13], chronic, refractory cough [14, 15], diabetic neuropathy [16-20], fi-
bromyalgia syndrome [21, 22], hiccups (singultus) [23-29], hot flashes [30-39], 
insomnia [8], neuropathic pain [20, 40-42], adjunct therapy for postoperative pain 
[43-45], restless legs syndrome (RLS) [46-51], anxiety disorders [8, 52], and 
uremic pruritus [53-56].  
On July 1, 2017, gabapentin became a Schedule V controlled substance in Ken-
tucky after several post-mortem toxicology reports in people with Opioid Use 
Disorder (OUD) revealed high levels of gabapentin in addition to opioids.  
Gabapentin has previously been touted for its low side effect profile and low ad-
diction potential.  Therefore, the medication has been widely prescribed, espe-
cially as an effective drug to treat chronic, neuropathic pain.   Physicians in Ken-
tucky may have been discouraged from prescribing gabapentin for any other in-
dications after adding it to the states’ list of controlled substances.  Although 
some studies have asserted that gabapentin is being abused as a way to in-
crease the “high” experienced with opioids, it is unclear how prevalent this prac-
tice is, who is abusing the medication, and whether it was prescribed or obtained 
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illegally.  Therefore, it would be important to learn more about the current uses of 
the medication and ensure that current laws and regulations support these indi-
cations in a way that protects all individuals’ right to health and safety.  Finally, 
this Capstone aimed to bridge the gap between the public health and clinical per-
spective on gabapentin.    
Historical Background
The Food and Drug Administration (FDA) initially approved gabapentin in De-
cember of 1993 as an adjunctive therapy in the treatment of partial seizures in 
patients over twelve years of age with epilepsy.  In October of 2000, the FDA ap-
proved gabapentin for use in anyone over three years of age for this indication.  
In May of 2004, it was also approved for postherpetic neuralgia in adults [1]. A 
precursor of gabapentin, called gabapentin enacarbil was approved in 2011 for 
the treatment of restless legs syndrome (RLS) [2].  In addition, pregabalin, a 
structural analog of gabapentin, is FDA approved to treat neuropathic pain, fi-
bromyalgia, postherpetic neuralgia, diabetic peripheral neuropathy, and 
epilepsy[3].    
Gabapentin has widely been prescribed for off-label indications.   An off-label in-
dication is the use of a medication for any population or disease for which the 
pharmaceutical company has not performed extensive randomized control trials 
to obtain FDA approval specifically for the indication.  Reasons for not obtaining 
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FDA approval for a particular indication include lack of a financial incentive or not 
wanting to test the medication in certain populations such as pregnant women 
and children.  Off-label indications for gabapentin include alcohol dependence [4-
6] and withdrawal [7], bipolar disorder [8], brachioradial pruritus [9-13], chronic, 
refractory cough [14, 15], diabetic neuropathy [16-20], fibromyalgia syndrome 
[21, 22], hiccups (singultus) [23-29], hot flashes [30-39], insomnia [8], neuropath-
ic pain [20, 40-42], adjunct therapy for postoperative pain [43-45], restless legs 
syndrome (RLS) [46-51], anxiety disorders [8, 52], and uremic pruritus [53-56].  
The mechanism of action for gabapentin is still partially unclear leading to some 
uncertainty about gabapentin.  It is thought to be structurally related to gamma-
aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central ner-
vous system of mammals.  Gabapentin does not appear to influence the synthe-
sis or uptake of GABA, however, nor does it bind to GABAA or GABAB receptors. 
Gabapentin is thought to bind to the α2δ subunit of presynaptic voltage-gated 
calcium channels located throughout the brain.  Further, it is believed that 
gabapentin modulates the release of excitatory neurotransmitters involved in 
epileptogenesis and nociception [57].  
Pre- and post-approval clinical trials of gabapentin did not reveal significant signs 
of dependence, in addition to a fairly benign safety profile [58].   As a result of the 
safety profile and off-label indications, the medication has been widely pre-
scribed.   
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In response to the opioid epidemic, Kentucky expanded the post-mortem toxicol-
ogy panel performed on people dying as a result of an opioid overdose.  After 
several post-mortem toxicology reports in people with Opioid Use Disorder re-
vealed high levels of gabapentin in addition to opioids, gabapentin became a 
Schedule V controlled substance in Kentucky.  This may affect the prescribing of 
gabapentin, especially for all its off-label indications.   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LITERATURE REVIEW
The purpose of the literature review was to determine the various off-label indica-
tions for gabapentin and advantages over other drugs and interventions used for 
this indication.  In addition, a secondary objective was to determine whether 
gabapentin is being misused and under what circumstances should the medica-
tion be used with more caution.   
The following review of the literature is a summary of key concepts foundational 
to understanding the off-label indications and misuse potential of gabapentin. It 
represents theoretical and empirical knowledge gathered from the disciplines of 
medicine and public health.  The works cited are collected from published journal 
articles published from January 2000 to February 2018.  The National Library of 
Medicine database (PubMed) and Uptodate websites were used as the database 
for the literature review, as well as conference proceedings, papers, reports, bib-
liographies, and reference lists.  Key words and phrases for the searches includ-
ed  “gabapentin off-label use,” “gabapentin off-label indications,” “gabapentin 
misuse,” and “gabapentin prescribing.”   A secondary review of writings refer-
enced in the bibliographies of key works and those recommended by experts, 
peers, and colleagues augmented the process.  
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Off-label uses of Gabapentin
Alcohol dependence and withdrawal 
Three randomized control studies investigated the use of gabapentin to treat al-
cohol dependence and withdrawal. One study found that after seven days of 
detoxification treatment with diazepam and vitamins for acute alcohol withdrawal, 
a four-week course of gabapentin (300 mg twice daily) for four weeks reduces 
the number of drinks per day and number of heavy drinking days and increases 
percentage of days of abstinence, compared to placebo [5].  A second study 
found that a twelve-week course of gabapentin (1800 mg/day) effectively in 
treats alcohol dependence and relapse-related symptoms of insomnia, dyspho-
ria, and craving [6].  The third study confirmed the latter, finding that even six 
weeks after treatment ended, gabapentin significantly delayed the onset to heavy 
drinking in patients with alcohol dependence and insomnia.  Furthermore, these 
patients were less likely to feel tired and drowsy in the morning compared to al-
cohol-dependent patients treated with trazodone [4].    
Brachioradial pruritus 
Brachioradial pruritus is often refractory to treatment with topical or oral corticos-
teroids and antihistamines, capsaicin and cervical spine manipulation.  However, 
brachioradial pruritus can be successfully treated with gabapentin at a dose of 
100- 600 mg three times daily [9, 11-13].  
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Chronic, refractory cough 
Out of the randomized control trials reviewed by the American College of Chest 
Physicians for the treatment of unexplained chronic cough, only gabapentin had 
sufficient, unbiased evidence to recommend its use.  In particular, inhaled corti-
costeroids were affected by intervention fidelity bias, esomeprazole was only ef-
fective in patients with gastroesophageal acid reflux and morphine is not a viable 
long-term option in light of the opioid epidemic [14].
The recommended daily dose of gabapentin is between 300 to 1800 mg per day 
[15].
Diabetic neuropathy  
Based on an extensive review of randomized control studies, the European Fed-
eration of Neurological Societies recommend tricyclic antidepressants (TCA), 
gabapentin, pregabalin and serotonin–norepinephrine reuptake inhibitors  
(SNRIs; duloxetine and venlafaxine) as first-line treatment for diabetic peripheral 
neuropathy (level A) [16].  
The American Academy of Neurology, American Association of Neuromuscular 
and Electrodiagnostic Medicine, and American Academy of Physical Medicine 
and Rehabilitation performed a systematic review of the literature from 1960 to 
August 2008 and recommends pregabalin as the treatment of choice for painful 
diabetic neuropathy (Level A).  Second-line treatment for painful diabetic neu-
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ropathy includes venlafaxine, duloxetine, amitriptyline, gabapentin (900-3600 mg 
per day), valproate, opioids (morphine sulfate, tramadol, and oxycodone con-
trolled-release), and capsaicin (Level B). [17]
The American Diabetes Association recommends pregabalin or duloxetine as the 
treatment of choice for diabetic neuropathy (Level A).  After taking into account 
patients’ socioeconomic status, comorbidities, and potential drug interactions, 
gabapentin was also recommended as a treatment of choice for diabetic neu-
ropathy (Level B) [19].
Fibromyalgia 
A 2017 Cochrane review concluded that there is insufficient evidence to support 
or refute the use of gabapentin for fibromyalgia as only one high-quality study 
has been performed.  This does not mean that gabapentin does not effectively 
treat fibromyalgia; rather, there are not enough high-quality studies done to show 
its effect.  Unfortunately, there are few other effective treatments for fibromyalgia. 
Often, this results in physicians treating patients with gabapentin when other 
treatments and interventions fail or are not a viable option [59]. The one high 
quality study that exists, a twelve-week, multi-center, double-blind randomized 
control trial, found that 91% of participants treated with gabapentin (1,200-2,400 
mg/day) felt better and about half of the participants treated with gabapentin 
achieved a 30% or greater reduction in pain over baseline [21].
 10
Hiccups (singultus) 
A 2015 systemic review concluded that baclofen and gabapentin are the first-line 
therapy for persistent and intractable hiccups while metoclopramide and chlor-
promazine are second-line agents [60].  Gabapentin effectively treats refractory 
hiccups in patients with co-morbidities including intention tremors, metastatic 
colon cancer, metastatic small cell lung cancer, pancreatic cancer, gastric cancer, 
coronary artery disease, COPD, diabetes mellitus, hiatal hernia, seminoma, lat-
eral medullary infarct, and alcoholism [23, 24, 28, 29].  The effective dose ranges 
from 100 mg to 400 mg three times per day. [23, 24, 26]  Patients continue to 
remain asymptomatic after three years. [27]
Hot flashes
The American College of Obstetrics and Gynecology as well as systemic reviews 
of the literature found good or consistent scientific evidence to conclude that 
gabapentin effectively treats hot flashes and vasomotor symptoms related to 
menopause and is a viable alternative to hormone therapy [30, 31, 38]. Specifi-
cally, a twelve-week course of gabapentin 900 mg per day led to a 50% reduction 
in the frequency and intensity of hot flashes from baseline [33].  Another study 
showed that gabapentin works just as well as estrogen in treating hot flashes, 
without the added risk of breast cancer [37].  Gabapentin (600 mg am/1,200 mg 
pm) showed similar effects in menopausal women with moderate to severe hot 
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flashes.  In addition, the drug significantly reduced sleep interference [36].  
Gabapentin also decreases hot flashes in men with androgen ablation-related 
vasomotor dysfunction [35].
Insomnia 
At high doses, gabapentin may be associated with sedative effects [61]. There-
fore, gabapentin is often prescribed to treat insomnia in patients with co-morbidi-
ties.  In particular, using polysomnography, gabapentin has been shown to im-
prove sleep, especially slow-wave sleep (important for memory consolidation), in 
healthy people, as well as in patients with epilepsy, restless legs syndrome, and 
alcohol dependence [4].
Neuropathic pain 
After conducting a systematic review of randomized double-blind studies of oral 
and topical pharmacotherapy for neuropathic pain, the Neuropathic Pain Special 
Interest Group (NeuPSIG) of the International Association for the Study of Pain 
gave a strong recommendation for use of tricyclic antidepressants, serotonin-no-
radrenaline reuptake inhibitors, pregabalin, and gabapentin (900–3600 mg/day) 
as first-line agents in treating neuropathic pain. [20] 
After an extensive review of the literature performed by the National Institute for 
Health and Care Excellence (NICE), they concluded that capsaicin cream, 
gabapentin, morphine, nortriptyline and tramadol consistently reduced pain com-
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pared with placebo.  When cost is taken into account, it was determined that 
gabapentin has the highest net benefit and should be the treatment of choice for 
neuropathic pain [41].  The American College of Critical Care Medicine (ACCM) 
in conjunction with Society of Critical Care Medicine (SCCM) and American Soci-
ety of Health-System Pharmacists (ASHP) recommend either enterally (orally) 
administered gabapentin or carbamazepine, in addition to intravenous opioids, 
be prescribed for treatment of neuropathic pain in the intensive care setting [40].
Adjunct Therapy for Postoperative pain 
Two 2015 systematic reviews and meta-regression analyses of the use of 
gabapentin to prophylactically treat post-operative pain found that 300- 600 mg of 
oral gabapentin, one hour before surgery significantly decreased pain scores 
both within the first hour and the first day postoperatively, with the effect being 
the greatest in the first hour and gradually decreasing thereafter [43, 45].  One of 
the systematic reviews also looked at the effect of pregabalin in reducing the pain 
score and need for opiates in the first day.  Although pregabalin also reduced 
both, gabapentin had a more profound effect than did pregabalin [45].  In addi-
tion, both the 2015 meta-analyses and a 2007 meta-analysis found a statistically 
and clinically significant decrease (by 35%) in 24-hour opiate consumption, post-
operative nausea, vomiting, and pruritus [43, 44].   Furthermore, pain scores with 
movement were decreased during the first 24 hours at rest and at two, four, and 
twelve hours post-operatively [44].  
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Restless legs syndrome (RLS) 
The International Restless Legs Syndrome Study Group (IRLSSG), European 
Restless Legs Syndrome Study Group (EURLSSG) and RLS Foundation (RLS-
F) recommend α2δ ligands, such as gabapentin, for the prevention of dopamin-
ergic-induced augmentation in restless legs syndrome/Willis-Ekbom disease 
(RLS/WED) after the correction of low iron levels and elimination of culprit anti-
depressants or antihistamines [51].  Gabapentin (300–1,200 mg) is similar in ef-
fectiveness and tolerability to ropinirole (0.25–1.50 mg), with respect to improve-
ment of RLS, reduction of periodic leg movements and side effects [47].  
Anxiety disorders 
Gabapentin has anxiolytic effects at therapeutic doses [58].  Specifically, in a 
placebo-controlled study, gabapentin was superior in treating social phobia at 
900 - 3,600 mg daily in three divided doses, over 14 weeks [52].  
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Misuse, Abuse, Dependence and Diversion of Gabapentin 
Toxicity 
Gabapentin is renally excreted and therefore must be used with caution in pa-
tients with poor renal function.  One case series described two patients, both 
presenting with a three-day history of tremors involving their upper extremities.  
The first patient was a 78-year-old woman with a complex medical history requir-
ing a cocktail of chronic medications  including gabapentin (900 mg/day).  Physi1 -
cal examination confirmed bilateral upper extremity myoclonus without other as-
sociated symptoms.  Labs revealed acute kidney injury secondary to a recently 
increased furosemide (total dose of 60 mg, daily) and lisinopril 5 mg daily, with 
hyperkalemia and azotemia. Gabapentin was discontinued and the myoclonus 
resolved after three days of hemodialysis.  
The second case of bilateral upper extremity myoclonus involved a 55-year-old 
man with a complex medical history including ESRD on peritoneal dialysis and 
multiple chronic medications .   The patient had been placed on a total daily dose 2
of 600 mg of gabapentin for neuropathic pain three days prior to admission, 
 Congestive heart failure, history of thromboembolism, hypertension, diabetes mellitus, 1
hyperlipidemia, asthma, diabetic peripheral neuropathy, and depression treated with 
simvastatin, metformin, citalopram, fluticasone proprionate inhaler, inhaled albuterol, 
lisinopril, furosemide, and metolazone.
 Anemia, diabetes mellitus, hypertension, neuropathic pain, hyperlipidemia, hepatitis C, 2
peripheral vascular disease with recently amputated gangrenous toe and acute pain 
syndrome treated with clopidogrel, amlodipine, hydralazine, metoprolol, clonidine, ator-
vastatin, oxycodone, hydromorphone, long-term vancomycin and piperacillin/tazobac-
tam, sevelamer, lanthanum, epoetin, and insulin glargine.
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which precipitated the chief complaint along with altered mental status, hypoten-
sion, and worsening leg infection.  After increasing the frequency of dialysis for 
four days and discontinuing gabapentin, the patient’s acute symptoms resolved.  
The latter two cases show that gabapentin should be used with caution in pa-
tients with a severe, complex medical history, particularly poor renal function.  
Furthermore, there is a threshold effect for the development of myoclonus sec-
ondary to gabapentin; serum concentrations of gabapentin should be kept under 
15 μg/mL to avoid symptomatic toxicity.  Of note, metformin, citalopram, al-
buterol, amlodipine, oxycodone, and hydromorphone can also lead to myoclonus 
[62]. 
Overdose 
In the event of a gabapentin overdose, it is extremely rare to have long-term se-
quelae.  Adverse effects secondary to acute-on-chronic overdose usually develop 
within two to four hours and resolve within ten hours.  Two overdoses illustrate 
this point: a 16-year-old female who ingested more than a one-and-a-half month 
supply of gabapentin (48.9 grams) developed diarrhea, dizziness, and lethargy 
that resolved within 18 hours, and a 32-year-old man who took about a three-
month supply (91 grams) of gabapentin, in addition to valproic acid and alcohol 
developed drowsiness, dizziness, slurred speech, and nystagmus, which all re-
solved within 11 hours.  Between 2000-2001, 4,837 gabapentin-only exposures 
were reported to the American Association of Poison Control Centers (AAPCC) 
 16
Toxic Exposure Surveillance System.  Of these, no medical adverse effects were 
seen in 1,353 individuals, minor effects were seen in 913, moderate effects in 
279, major effects in 25, and deaths were reported in three people.  Doses asso-
ciated with the three fatalities were 16.5 g, 48 g, and 59.4 g (about a 15-, 45- and 
60-day dose, respectively) [63].  
Fatalities associated with polysubstance use are more common.  Mortality data 
from the Kentucky Drug Overdose Fatality Surveillance System (DOFSS) 
showed that of the decedents with postmortem toxicology studies, gabapentin 
was found in one third of overdose deaths and almost half of overdose deaths in 
decedents with a history of mental illness.  It was more frequently found in female 
decedents over 44 years of age [64].  
A 2017 systemic review called into question whether gabapentinoids (gabapentin 
pegabalin and related derivatives) are the culprits in overdose deaths in people 
with opiate and polyvalent use disorder.  Furthermore, fatalities were predomi-
nantly associated with pregabalin and not gabapentin [58].    
Dependence
Dependence on a drug can either be physical or psychological and includes 
symptoms of withdrawal, tolerance and compulsion [65].  A 2017 systemic review 
by a German team looked at the risk of dependence on gabapentinoids.  Of the 
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four individuals cited in the literature that met the criteria for behavioral depen-
dence on gabapentinoids, not associated with other substance use disorders 
(other than nicotine), all had used pregabalin as opposed to gabapentin.  The 
risks of behavioral and physical dependence on gabapentinoids were greater in 
pregabalin, compared to gabapentin, and the risk of harm and dependence on 
both medications were infrequent compared to other sedatives and stimulants.   
Having said this, the authors concluded that if possible, use of gabapentinoids 
should be prescribe cautiously and for a limited period of time in patients with 
current or prior substance use disorders [58].   
The National Institute for Health and Care Excellence (NICE) did not find any ev-
idence for dependence on gabapentin or pregabalin, in contrast to opioids.  Fur-
thermore, NICE was concerned that people with a history of substance use dis-
order may be denied treatment.  Thus, they recommend that the risks and bene-
fits of treatment be weighed on an individual basis [41].  
Misuse 
Misuse of a medication is when an individual takes the medication in a way other 
than how it was intended.  For example, taking a higher dose than prescribed, a 
route of administration other than prescribed (e.g. inhalation instead of ingestion), 
or diversion—intentional or unintentional sharing of prescription medication with 
anyone other than the intended patient [65].  
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Two 2017 systemic reviews, one performed by a team at the University of Ken-
tucky and another at the University of Texas, cited gabapentin misuse to be be-
tween 15-22%, among patients with a history of Opioid Use Disorder (OUD) liv-
ing in the United States and United Kingdom (UK), with 40% claiming to use 
more than prescribed and 13% using nonprescribed gabapentin [65, 66].  In con-
trast, no gabapentin misuse was cited among individuals with a history of alcohol 
dependence, even among those who also had OUD [65].  With respect to the 
general population, 1.1% of a UK population-based sample of 1500 individuals 
between 16-59 years of age reported ever misusing gabapentin.  In contrast, 
28.1% and 9.1% reported using cannabis and cocaine, respectively [66].
Reports from Sweden indicate that pregabalin, but not gabapentin is being mis-
used.  Of the 198 reports of drug misuse or addiction in the Swedish database 
between 1980 and 2009, 16 reports of pregabalin misuse were identified but not 
a single report of gabapentin misuse.  However, review of anecdotal online data 
did yield reports of recreational misuse of both drugs [61].  Diversion may also be 
taking place in the United States.  Of 503 adults from Appalachian Kentucky with 
OUD, not currently in treatment, 15% claimed they used gabapentin “to get high” 
in the past six months.  Most identified either providers or drug dealers as the 
source of the gabapentin [68].  Gabapentin reportably has a street value ranging 
from one to seven dollars per pill [66].  
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The University of Texas team concluded that the misuse of gabapentinoids occur 
predominantly in high-risk populations and are less common than that of other 
drugs.  Furthermore, given their important role in treating several chronic dis-
eases, the evidence does not support its restriction, but rather emphasizing the 
importance of identifying risk factors and signs of misuse [66]. 
The purpose of this study was to determine the various real-life off-label uses of 
gabapentin and physician perspectives with regard to particular advantages over 
other drugs and interventions.  In addition, a secondary objective was to deter-
mine physicians’ perspectives regarding whether gabapentin is being misused 
and should be more strictly regulated.   By addressing these two objectives, the 
study helps physicians to optimize prescribing practices in order to enhance pa-




An observational cross-sectional study was used to explore the clinical reasoning 
used by physicians when prescribing gabapentin for off-label indications, via an 
online survey tool. 
Study Population and Sampling Strategy
The target population was any physician who prescribes gabapentin in the world.  
Since the purpose of the project was to identify factors being considered when 
prescribing gabapentin and not necessarily the prevalence of these factors, a 
convenience sample was used.  Personal contacts that are physicians were sent 
an invitation e-mail including a link to an online survey (using secured University 
of Kentucky Qualtrics survey tools) and cover letter with a brief description of the 
purpose of the survey.  Personal contacts were encouraged to invite their fellow 
physicians to take the survey as well.  Less than 20 personal contacts were 
asked to participate. Some personal contacts sent the survey out to their entire 
department.
Physicians working both in and outside of Kentucky were asked to participate in 
order to obtain a large enough sample of physicians. The ages of the physicians 
are presumable between 24 to 90 years.  Both men and women, of any ethnic 
background that are healthy enough to practice medicine were welcome to take 
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the survey.  The proposed sample composition of physicians was about 15 Pri-
mary Care Physicians/Psychiatrists and 5 Emergency Medicine/Urgent Care 
physicians.  Inclusion criteria included being a physician practicing medicine that 
prescribes gabapentin or treats patients prescribed gabapentin by another physi-
cian.  
Study Measures
Physicians that provide continuity of care (all physicians except Emergency Med-
icine physicians) were asked whether they prescribe gabapentin, if so, how often 
and for what indications.  For off-label indications, they were asked to discuss the 
advantages of gabapentin over other medications and interventions for the indi-
cation.  To determine physicians’ thoughts and attitudes regarding its misuse and 
overdose potential, Emergency Medicine physicians were asked about their ex-
periences with misuses and overdoses associated with gabapentin, as they are 
most often the ones treating acute adverse events.  Survey questions are includ-
ed in Appendix A.
Data Collection Tools and Analytic Strategy
The secured University of Kentucky Qualtrics survey tools were used to create 
an online survey to explore the clinical reasoning used by physicians when pre-
scribing gabapentin for off-label indications.  Enrollment began on February 7th, 
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2018 after the study was approved by the IRB committee and ended on April 
2nd, 2018.  Once surveys were received, the responses to each question were 
examined to look for an overall consensus and any sort of unique patient profile.  
For example, women in their twenties with diagnosis X that have co-morbidities 
Y, are also on medication Z, and have not responded to medications A, B, and C.  
The responses were examined according to specialty.  All analyses were con-
ducted using Microsoft Excel software.
Ethical Considerations
The study was reviewed and approved by the University of Kentucky Internal Re-




The study participants who responded to the Qualtrics survey included 17 Family 
Medicine physicians, 12 Psychiatrists, 9 Emergency Medicine physicians, two 
Neurologists, two Internists, two Other physicians (one of which was an Addiction 
Medicine specialist), one Intensivist physician, one Occupational Medicine physi-
cian, Pediatrician, Pulmonologist, Rheumatologist, and Surgeon (Table 1), of 
which 39 out of 41 prescribe gabapentin (the Intensivist and one Internist did not; 
Table 2 and Figure 2).  Emergency Medicine physicians were not asked whether 
or not they prescribed gabapentin because they do not provide continuity of care 
and do not regularly initiate medications for chronic conditions.  
Table 1.  Frequency and Percentage of Participants by Clinical Specialty 
FM= Family Medicine, EM= Emergency Medicine, Psych= Psychiatry, IM= Internal Medicine, Neuro= Neurology, Occ 
Med= Occupational Medicine, Peds= Pediatrics, Pulm= Pulmonology, Rheum= Rheumatology
Table 2.  Frequency and Percentage of Gabapentin Prescriptions by Clinical Specialty 
FM= Family Medicine, EM= Emergency Medicine, Psych= Psychiatry, IM= Internal Medicine, Neuro= Neurology, Occ 
Med= Occupational Medicine, Peds= Pediatrics, Pulm= Pulmonology, Rheum= Rheumatology




Peds Pulm Rheum Surgery
Number 17 9 12 2 2 2 1 1 1 1 1 1
Percentag
e
34% 18% 24% 4% 4% 4% 2% 2% 2% 2% 2% 2%




Peds Pulm Rheum Surgery
Number 17 12 2 2 2 1 1 1 1 1 1





Figure 2. Frequency Distribution of Physicians Prescribing Gabapentin  
The majority (21 out of 39 physicians) 
reported that ten percent or fewer of their 
patients were taking gabapentin (Figure 
3). Less than one third reported that 
11-20% of their patients were taking 
gabapentin (12 out of 39) and six physi-
cians reported 21-50% of their patients 
were taking the medication.  No physi-
cian reported a number over 50%.  
The Surgeon had the highest proportion of patients on the medication (41-50%), 
followed by Family Medicine physicians and then Psychiatrists (Table 3 and Fig-
ure 4).  The “Other” physician wrote that prior to gabapentin becoming a sched-
uled medication, 50-60% of his or her patients were on the medication.  Now it is 
between zero to ten percent. 
Table 3  Percentage of Patients taking Gabapentin by Clinical Specialty 
FM= Family Medicine, EM= Emergency Medicine, Psych= Psychiatry, IM= Internal Medicine, Neuro= Neurology, Occ 
Med= Occupational Medicine, Peds= Pediatrics, Pulm= Pulmonology, Rheum= Rheumatology
Specialty FM Psych Neuro Other Occ 
Med
Peds Pulm Rheum Surgery
0-10% 59% 33% 100% 100% 100% 100% 0% 0% 50%
11-20% 18% 58% 0% 0% 0% 0% 100% 100% 0%
21-30% 18% 8% 0% 0% 0% 0% 0% 0% 0%
31-40% 6% 0% 0% 0% 0% 0% 0% 0% 0%
41-50% 0% 0% 0% 0% 0% 0% 0% 0% 50%
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Figure 3 Distribution of Gabapentin Prescriptions
 About half of the physicians with patients 
on gabapentin initiated the medication 
(Figure 5).  Psychiatrists reported to plac-
ing a higher proportion of their patients 
on gabapentin than other physicians, with 
one of the Psychiatrists reporting to have 
initiated the prescription for 81-90% of his 
or her patients that are currently on 
gabapentin (Table 4).  Family Medicine 
physicians were the second most likely to 
initiate the prescription, whereas the others 
surveyed rarely initiated the prescription. 




















Figure 4 Percentage of Patients taking Gabapentin by Clinical Specialty 
Figure 5 Percentage and Frequency Distribution of Pa-
tients Started on Gabapentin
Table 4  Percentage of Patients started on Gabapentin by Clinical Specialty 
FM= Family Medicine, EM= Emergency Medicine, Psych= Psychiatry, IM= Internal Medicine, Neuro= Neurology, Occ 
Med= Occupational Medicine, Peds= Pediatrics, Pulm= Pulmonology, Rheum= Rheumatology
 
Figure 6 Percentages and Frequency Distribution of Patients Started on Gabapentin by Clinical 
Specialty
Specialty FM Psych Neuro Other Occ Med Peds Pulm Rheum Surgery
0-10% 47% 33% 100% 100% 100% 100% 100% 100% 100%
11-20% 20% 17% 0% 0% 0% 0% 0% 0% 0%
21-30% 13% 8% 0% 0% 0% 0% 0% 0% 0%
31-40% 0% 8% 0% 0% 0% 0% 0% 0% 0%
41-50% 7% 8% 0% 0% 0% 0% 0% 0% 0%
51-60% 0% 0% 0% 0% 0% 0% 0% 0% 0%
61-70% 7% 8% 0% 0% 0% 0% 0% 0% 0%
71-80% 7% 8% 0% 0% 0% 0% 0% 0% 0%
81-90% 0% 8% 0% 0% 0% 0% 0% 0% 0%
Of your patients taking gabapentin, what 






















Conditions For Which Gabapentin is Prescribed
Among respondents to the survey, neuropathic pain was the most common indi-
cation for prescribing gabapentin, followed by diabetic neuropathy, fibromyalgia 
and postherpetic neuralgia (Appendix B).  Alcohol dependence or withdrawal and 
anxiety disorders were the most common indication for which the FDA has yet to 
approve a gabapentinoid, followed by insomnia.  All 17 of the Family Medicine 
physicians had prescribed gabapentin for neuropathic pain, 16 of the 17 had pre-
scribed it for diabetic neuropathy, approximately half for fibromyalgia, and ten out 
of 17 for postherpetic neuralgia (Table 5 and Figure 7).  Psychiatrists most com-
monly prescribed gabapentin for anxiety disorders, followed by insomnia.  The 
same number of Psychiatrists prescribed gabapentin for neuropathic pain as for 
alcohol dependence.  Interestingly, neither of the Neurologists prescribed 
gabapentin for partial seizures, although one Family Medicine physician and the 
Pediatrician prescribed gabapentin for partial seizures.  None of the Psychiatrists 
prescribed gabapentin for cocaine withdrawal, although one of the Family Medi-
cine physicians had prescribed the medication for cocaine withdrawal.  As ex-
pected, the Pulmonologist had prescribed gabapentin for chronic cough.   Two of 
the Psychiatrists and one of the Family Medicine physicians prescribed 
gabapentin for bipolar disorder.  In addition to the eight Family Medicine physi-
cians, five of the Psychiatrists and the Rheumatologist had prescribed 
gabapentin for fibromyalgia.  Two Family Medicine physicians, a Psychiatrist and 
the Surgeon, also prescribed the medication for cancer-related hot flashes and 
brachioradial pruritus.  One Family Medicine physician prescribed gabapentin for 
 29
postoperative pain and another Family Medicine physician prescribed it for 
menopause-related hot flashes.  Gabapentin is the drug of choice for one of the 
Psychiatrists for insomnia in patients with alcoholism; otherwise the Psychiatrist 
prescribes it as a second-line agent for insomnia.  Another Psychiatrist pre-
scribed gabapentin second-line for anxiety in patients that did not respond to se-
lective serotonin reuptake inhibitors (SSRIs), in order to avoid the use of a ben-
zodiazepine. The Psychiatrist also prescribed gabapentin in patients developing 
anxiety secondary to cannabis use discontinuation. 
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Table 5  Percentage of Physicians in Specialty prescribing Gabapentin for each Clinical Indication
FM= Family Medicine, EM= Emergency Medicine, Psych= Psychiatry, IM= Internal Medicine, Neuro= Neurology, Occ 























7% 0% 0% 0% 0% 0% 100% 0% 0% 0%
Postherpetic 
Neuralgia
59% 8% 50% 50% 0% 0% 0% 0% 0% 0%
Restless Legs 
Syndrome
41% 25% 0% 0% 50% 0% 0% 0% 0% 0%
Cocaine 
withdrawal
6% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Insomnia 12% 67% 0% 0% 0% 0% 0% 0% 0% 0%
Diabetic 
neuropathy




6% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Anxiety 
disorder
6% 83% 0% 0% 0% 0% 0% 0% 0% 0%
Bipolar 
disorder
6% 17% 0% 0% 0% 0% 0% 0% 0% 0%
Alcohol 
dependence
24% 50% 0% 0% 50% 0% 0% 0% 0% 0%
Brachioradial 
pruritus
6% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Chronic 
cough
0% 0% 0% 0% 0% 0% 0% 100% 0% 0%
Fibromyalgia 47% 42% 0% 0% 0% 0% 0% 0% 100% 0%
Postoperative 
pain
12% 8% 0% 0% 0% 0% 0% 0% 0% 100%
Neuropathic 
pain
100% 50% 50% 100% 0% 100% 0% 0% 100% 0%
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  
 Figure 7  Frequency Distribution of Physicians in Clinical Specialty prescribing Gabapentin for 
each Clinical Indication
Restless Legs Syndrome (RLS)
Eleven physicians (seven Family Medicine physicians, three Psychiatrists, and 
one “other” physician) prescribed gabapentin for RLS (Figure 7).  Ropinirole was 
the most common drug of choice, followed by 
pramipexole, prescribed by five and four Family 
Medicine physicians, respectively (One Family 
Medicine physician had written the two medica-
tions in as a comment as opposed to selecting 
the box; Figure 8 and Table 6).  One of 
the Psychiatrists also prescribed 
ropinirole prior to gabapentin.  One Family Medicine physician, Psychiatrist, and 
“other” physician prescribed gabapentin as the drug of choice.  One Family Med-
For which of the following clinical 































































Frequency Distribution of Medications prescribed for Restless 











icine physician preferred pregabalin, while another reported that most of his or 
her patients with RLS were inherited and therefore already on a medication.  
However, he or she commented that pregabalin is not always paid for by insur-
ance and is a controlled substance, making gabapentin more appealing.  Another 
Family Medicine physician stated that gabapentin is prescribed when there is a 
contraindication to the other medications.  One of the Psychiatrists had com-
mented that he or she does not usually treat RLS but that if the patient has a co-
morbidity such as anxiety or insomnia, gabapentin is the drug of choice for treat-
ing the co-morbidity in a patient with RLS.  
Table 6  Percentage of Physicians in Clinical Specialty Prescribing Alternative Treatment or Inter-
vention Prior and/or In Addition to Gabapentin for the Treatment of Restless Legs Syndrome





Pramipexole 18% 0% 0%
Ropinirole 24% 8% 0%
Pregabalin 6% 0% 0%
None 6% 8% 50%
Other 6% 0% 0%
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Cocaine Withdrawal
One Family Medicine physician prescribed gabapentin for cocaine withdrawal.  
He or she also prescribed benzodiazepines, doxepin, clonidine, and modafinil in 
addition or prior to gabapentin.  
Insomnia
Ten physicians (eight Psychiatrists and two Family Medicine physicians) pre-
scribed gabapentin for insomnia (Figure 7). Melatonin was the drug of choice for 
Psychiatrists (Figure 9 and Table 7).  Second-line therapy included zolpidem, lo-
razepam, and behavioral therapy, followed by doxepin and diphenhydramine, 
then eszopiclone and diazepam.  Psychiatrists also tried zaleplon, suvorexant, 
ramelteon, melatonin agonists, and flurazepam.  One Psychiatrist would use mir-
tazapine and quetiapine only if the patient had co-morbidities such as mood dis-
orders.  Another Psychiatrist would only use gabapentin for insomnia in patients 
with refractory insomnia such as patients with primary depression.  The Psychia-
trist prescribed gabapentin in addition to benzodiazepines or hypnotics if the lat-
ter are insufficient.  Trazodone was another medication prescribed by the Psy-
chiatrist.  Family Medicine physicians tried behavioral therapy, melatonin, zolpi-
dem, lorazepam, doxepin, diphenhydramine, eszopiclone, zaleplon, melatonin 
agonist and triazolam.  One Family Medicine physician added that he or she 
starts with non-pharmaceutical approaches, followed by melatonin, antihista-
mines, TCAs, and trazodone. 
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Figure 9 Frequency Distribution of Medications prescribed for Insomnia by Physicians Who Also 
Prescribe Gabapentin for the Indication
Table 7  Percentage of Physicians in Clinical Specialty Prescribing Alternative Treatment or Inter-

































Behavioral therapy 6% 42%
Melatonin 6% 50%
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FM= Family Medicine, Psych= Psychiatry 
Diabetic Neuropathy
Sixteen Family Medicine physicians and one Psychiatrist, Neurologist, and In-
ternist prescribed gabapentin for diabetic neuropathy (Figure 7).  Amitriptyline 
was the most popular medication, selected by ten Family Medicine physicians, 
the Internist and one of the Neurologists (Figure 10).  The second most common 
medication was duloxetine, which was prescribed by seven Family Medicine 
physicians, one Psychiatrist and Neurologist, followed by venlafaxine, prescribed 
by five Family Medicine physicians.  Pregabalin was prescribed by five Family 
Medicine physicians and one Neurologist.  Nortriptyline was prescribed by four 
Family Medicine physicians and one Neurologist.  Three Family Medicine physi-
cians and one Neurologist prescribed carbamazepine and a lidocaine patch.  
However, one of the Family Medicine physicians commented that although car-
bamazepine has been prescribed, it was prescribed as an alternative treatment 
when all else failed.  Five Family Medicine physicians also prescribed venlafax-
ine, four prescribed capsaicin and three prescribed tramadol.  Two Family Medi-
cine physicians and one Neurologist prescribed Transcutaneous Electrical Nerve 
Stimulation (TENS), three Family Medicine physicians prescribed gabapentin as 
the drug of choice for diabetic neuropathy (one Family Medicine physician wrote 
it in as a comment), two Family Medicine physicians prescribed ibuprofen, and 
one prescribed acetyl-L-carnitine, valproate and doxepin.  One Family Medicine 
physician had stated that getting the patients’ blood glucose levels under control 
is done prior to prescribing any medications.  One of the nine Family Medicine 
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physicians that prescribed amitriptyline first-line said that the medication did not 
work in 50-80% of patients so gabapentin is prescribed second-line.  Another 
Family Medicine physician used non-controlled medications prior to trying con-
trolled medications.  
 
Figure 10 Frequency Distribution of Medications prescribed for Diabetic Neuropathy by Physi-

























Two physicians, both Family Medicine physicians, prescribed gabapentin for hot 
flashes, one for cancer-related hot flashes and the other for menopause-related 
hot flashes (Figure 7). The physician that prescribed gabapentin for cancer-relat-
ed hot flashes also tried venlafaxine and paroxetine (Figure 11).  The physician 
that prescribed gabapentin for menopause-related hot flashes also tried estrogen 
replacement therapy and paroxetine. 
 
Figure 11 Frequency Distribution of Medications prescribed for Hot Flashes by Physicians Who 









Ten Psychiatrists and one Family Medicine physician prescribed gabapentin to 
treat anxiety disorders (Figure 7).  SSRIs (sertraline, citalopram and escitalo-
pram) were the drugs of choice, followed by the benzodiazepines clonazepam 
and lorazepam, then SNRIs venlafaxine and duloxetine (Figure 12).  Three Psy-
chiatrists also prescribed fluoxetine, buspirone, paroxetine and mirtazepine; two 
prescribed quetiapine and hydroxyzine, while one tried cognitive behavioral ther-
apy, fluvoxamine, alprazolam, and diazepam.  One Family Medicine physician 
also tried pregabalin, oxazepam, chlordiazepoxide, and chlorazepate.  Two of the 
Psychiatrists used gabapentin as the treatment of choice for patients with sub-
stance use disorders that also have anxiety.  Two Psychiatrists prescribed 
gabapentin second-line in place of benzodiazepines, which, one of the Psychia-
trists added “are more addictive and ‘much, much more’ dangerous.”  The same 
physician remarked that antidepressants cannot be prescribed on an as needed 
basis, as they take about 6 weeks to work.  One Psychiatrist commented “An-
tipsychotics should not be prescribed for anxiety if a medication with fewer side 
effects (gabapentin), is available.”  Another Psychiatrist used gabapentin in pa-
tients with either cannabis use disorder or neuropathic pain, in addition to anxi-
ety.  Finally, a fourth psychiatrist commented that he or she used gabapentin only 
for treatment-refractory depression as a last resort.  
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Figure 12 Frequency Distribution of Medications prescribed for Anxiety by Physicians Who Also 


















Two Psychiatrists and one Family Medicine physician used gabapentin for bipolar 
disorder (Figure 7).  Both Psychiatrists used lithium as first-line therapy (Figure 
13).  One Psychiatrist and one Family Medicine physician used psychotherapy, 
lamotrigine, valproate, divalproex, risperidone, olanzapine and aripiprazole.  One 
Psychiatrist used ziprasidone and one Family Medicine physician used carba-
mazepine, quetiapine, and asenapine (Figures 13 and 14).  
 
Figure 13 Frequency Distribution of Medications prescribed for Bipolar Disorder by Physicians 
Who Also Prescribe Gabapentin for the Indication According to Clinical Specialty
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Figure 14 Frequency Distribution of Medications prescribed for Bipolar Disorder by Physicians 


















Alcohol Withdrawal and Dependence
Eleven physicians (six Psychiatrists, four Family Medicine physicians, and the 
Addiction Medicine specialist) prescribed gabapentin for alcohol withdrawal or 
dependence (Figure 7).  The most common drug among the three specialties 
was lorazepam, with all four Family Medicine physicians, half of the Psychiatrists, 
and the Addiction Medicine specialist prescribing it (Figure 15).  The second most 
common drug among Psychiatrists was phenobarbital with two of the six Psychi-
atrist, one of the Family Medicine physicians and the Addiction Medicine special-
ist prescribing it.  Among the Family Medicine physicians, diazepam, folate, and 
thiamine were the second most common medications prescribed.  The Addiction 
Medicine specialist prescribed all three; one of the Psychiatrists prescribed folate 
and thiamine.  Two Family Medicine physicians prescribed clonidine, oxazepam, 
and isotonic saline with 5% dextrose.  One of the Psychiatrists and the Addiction 
Medicine specialist also prescribed clonidine.   One Psychiatrist and one Family 
Medicine physician prescribed a multivitamin and one Family Medicine physician 
had prescribed carbamazepine.  One of the Family Medicine physicians com-
mented that he or she also uses naltrexone, acamprosate, and disulfuram for al-
cohol-dependent patients pursuing abstinence.  Another Family Medicine physi-
cian added that he or she individualizes the treatment for each patient and 
gabapentin may be preferred over some of the other medications, depending on 
the patient.  One of the Psychiatrists added that gabapentin is the drug of choice, 
especially for patients in whom ongoing benzodiazepines are a “bad idea.”
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 
Figure 15 Frequency Distribution of Medications prescribed for Alcohol Withdrawal/Dependence 
by Physicians Who Also Prescribe Gabapentin for the Indication
Brachioradial Pruritus
One of the Family Medicine physicians prescribed gabapentin for brachioradial 
pruritus.  Lidocaine and amitriptyline were also tried (Figure 16).  
 
Figure 16 Frequency Distribution of Medications prescribed for Brachioradial Pruritus by Physi-
























The Pulmonologist prescribed gabapentin for chronic cough.  Cough suppression 
techniques, breathing exercises, guaifenesin, inhaled budesonide, and chlor-
pheniramine were also tried (Figure 17).  
 
Figure 17 Frequency Distribution of Medications prescribed for Chronic Cough by Physicians 
Who Also Prescribe Gabapentin for the Indication
Fibromyalgia
Fourteen physicians (eight Family Medicine physicians, five Psychiatrists, and 
the Rheumatologist) prescribed gabapentin for fibromyalgia (Figure 7).  All eight 
of the Family Medicine physicians, two of the Psychiatrists, and the Rheumatolo-
gist recommended exercise (Figure 18).  Seven Family Medicine physicians, one 
of the Psychiatrists and the Rheumatologist recommended physical therapy.  The 
most common answer choice among the Psychiatrists was duloxetine (three 
Psychiatrists); five of the Family Medicine physicians and the Rheumatologist 
also prescribed this medication.  Five Family Medicine physicians also prescribed 







0 0 1 1 1
Pulmonology
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the Psychiatrists were Cognitive Behavioral Therapy and yoga (two 
psychiatrists); the Rheumatologist also prescribed both of these interventions 
along with four and three Family Medicine physicians, respectively.  Four Family 
Medicine physicians and one Psychiatrist prescribed Venlafaxine.  Three Family 
Medicine physicians and one Psychiatrist recommended Tai Chi.  Three Family 
Medicine physicians prescribed cyclobenzaprine.  One physician had comment-
ed that he or she prefers muscle relaxers and uses tramadol and opioids in addi-
tion to another medication if the patient has other co-morbidities.  One Family 
Medicine physician prescribed milnacipran and Osteopathic Manipulation Thera-
py, each.  
 
Figure 18 Frequency Distribution of Medications prescribed for Fibromyalgia by Physicians Who 




















Two of the Family Medicine physicians, one of the Psychiatrists and the Surgeon 
prescribed gabapentin for post-operative pain (Figure 7).  In addition, one of the 
Family Medicine physicians prescribed tramadol, diclofenac, morphine, celecox-
ib, ketorolac, intravenous acetaminophen, lidocaine, meperidine, fentanyl and 
hydromorphone (Figure 19).  The Surgeon also prescribed tramadol, diclofenac, 
ibuprofen, and morphine.  One of the Psychiatrists prescribed ibuprofen.  
Gabapentin was prescribed by one of the Family Medicine physicians, as adju-
vant therapy in patients that did not respond to initial pain control.  
 
Figure 19 Frequency Distribution of Medications prescribed for Post-operative Pain by Physicians 
Who Also Prescribe Gabapentin for the Indication
Neuropathic Pain
Twenty-eight physicians (17 Family Medicine physicians, six Psychiatrists, two 
Neurologists, one Rheumatologist, Occupational Medicine physician, and In-


















medications were duloxetine followed by amitriptyline (Figure 20).  Nine Family 
Medicine physicians, a Psychiatrist, a Neurologist, the Occupational Medicine 
physician, and the Rheumatologist prescribed amitriptyline.  Ten Family Medicine 
physicians, two Psychiatrists, and a Neurologist prescribed duloxetine. Six Fami-
ly Medicine physicians, a Neurologist and the Rheumatologist prescribed prega-
balin.  Five Family Medicine physicians, the Occupational Medicine physician 
and Internist prescribed capsaicin and venlafaxine.  One of the Family Medicine 
physicians also used nerve stimulation and Osteopathic Manipulation Therapy.  
 
Figure 20 Frequency Distribution of Medications prescribed for Neuropathic Pain by Physicians 













































For the majority of conditions, gabapentin was not the drug of choice but was 
prescribed as a second or third-line agent when other medications had either 
failed or when a patient had co-morbidities that responded to gabapentin. First-
line agents included benzodiazepines, tricyclic antidepressants, and serotonin-
norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors.    
Some of the reasons for prescribing gabapentin included that the medication had 
the potential to help with more than one indication, it is generic, well-tolerated, 
safe, inexpensive, great response was seen in the past, has few side effects, not 
metabolized in the liver, the benefits outweighed the risks with respect to pain re-
lief, moderate evidence of efficacy from patient studies, failure to respond to non-
controlled medications, and/or all other medications and modalities.  As one 
physician put it, “For [off-label] indications you're usually going through a host of 
meds, none of which works completely, so gabapentin is a trial and you have to 
see the effects vs. risks for each patient vs. other meds.”  Several physicians 
mentioned that gabapentin is “far less addictive and toxic than other 
medications,” particularly benzodiazepines and tricyclic antidepressants, pre-
scribed for the same indication (See Appendix C and Influence of Substance Use 
Disorder, Opioid Use Disorder, and Opioid Prescription on Physician Prescribing 
of Gabapentin).  
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Experiences Discontinuing Gabapentin
The majority of physicians reported having successfully weaned patients off of 
gabapentin (Figure 21).  One of the Family Medicine physicians, who had re-
sponded “no,” said he or she has never tried to wean a patient off.  Two of the 
Psychiatrists added that they never had any issues with weaning.  Common rea-
sons for weaning included inconvenience now that it became a controlled med-
ication in Kentucky, poor kidney function, side effects such as sedation, word-
finding, and sleep ataxia, medication switch, failure of a random drug screen, 
concerns for misuse and overdose, and the inciting factor was resolved.  
 
Figure 21 Frequency Distribution of Physicians that have Successfully Weaned Patients Off 
Gabapentin by Medical Specialty















Influence of Substance Use Disorder, Opioid Use Disorder and Opioid Pre-
scription on Physician Prescribing of Gabapentin
Most of the Psychiatrists would be more likely to prescribe gabapentin to a pa-
tient with a history of Substance Use Disorder (SUD), whereas most of the Fami-
ly Medicine physicians would be less likely (Figure 22).  One of the Family Medi-
cine physicians commented that he or she would try not to prescribe it to people 
with SUD now that it is a controlled substance in Kentucky.  Another Family Med-
icine physician said he or she would be more likely to use gabapentin in a patient 
with alcohol dependence but that there is a “small real abuse or diversion poten-
tial” in patients with Opioid Use Disorder (OUD).  Another Family Medicine physi-
cian echoed this remark.  A fourth Family Medicine physician also mentioned 
heroin and opioid misuse as the reason to be less likely to prescribe gabapentin 
to a patient with SUD.  Finally, one of the Family Medicine physicians who would 
be more likely to prescribe gabapentin to a patient with SUD mentioned that if the 
patient had an appropriate indication, “gabapentin is far less risky than benzodi-
azepine or opioids and is a great substitute with good results in many cases.”  
Many of the Psychiatrists had echoed the latter Family Medicine physicians’ re-
marks, adding that they preferred gabapentin to benzodiazepines for the treat-
ment of anxiety.  Another Psychiatrists agreed that gabapentin is often a great 
alternative to benzodiazepines and has never seen a patient have the same 
withdrawal symptoms as seen with benzodiazepines.  A third Psychiatrist said his 
or her decision depends on the substance the patient was addicted to and the 
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patient’s response to alternative medicines.  A fourth Psychiatrist refers patients 
with SUD to specialists.  
 
Figure 22 Frequency Distribution Of Physicians Who’s Decision To Prescribe Gabapentin Would 
Be Influenced By Patient History of Substance Use Disorder (SUD)
With respect to the physicians who would be more likely to prescribe gabapentin 
to a patient with SUD, the Psychiatrists would either also be more likely to pre-
scribe gabapentin to a patient with OUD or the OUD would not influence their de-
cision, whereas one Family Medicine physician would be less likely to prescribe 
gabapentin to this patient (Figure 23).  Another Family Medicine physician com-
mented that it would depend on the reason—if the patient had a solid indication 
for an opioid, but did not want to prescribe the patient an opioid, gabapentin 
would be a good alternative.  One of the Psychiatrists had mentioned that 
If a patient had a history of 
SUD, would it influence your 
decision to prescribe 
gabapentin?
No Influence
LESS likely to prescribe it
MORE likely to prescribe it















gabapentin is a great alternative for other more addicting substances and anoth-
er Psychiatrist would use gabapentin to treat a patient with OUD and anxiety.  
 
Figure 23 Frequency Distribution Of Physicians Who’s Decision To Prescribe Gabapentin Would 
Be Influenced By Patient History of Opioid Use Disorder (OUD)
A patient’s use of opioids would make all but two Family Medicine physicians less 
likely to prescribe gabapentin (Figure 24).  One Family Physician would be more 
likely to prescribe gabapentin whereas the other Family Physician’s decision 
would be unaffected by having a patient on opioids.  The Family Medicine physi-
cian that would be more likely to prescribe gabapentin would use gabapentin to 
reduce a patient’s use of opioids.  Five Psychiatrists would be more likely to pre-
scribe gabapentin, one Psychiatrist would be less likely and four Psychiatrists’ 
decisions would not be influenced by the legitimate use of opioids.  The two Neu-
rologists appeared to agree with the consensus among the Psychiatrists—one 
would be more likely to prescribe gabapentin whereas the other’s decision would 
be unaffected, as would the Pulmonologist and Surgeon’s decisions.  The Occu-
If a patient had a history of OUD, 
would it influence your decision 
to prescribe gabapentin?
No influence
LESS likely to prescribe it
MORE likely to prescribe it







pational Medicine Physician, Pediatrician, Rheumatologist, and other physician 
would be less likely to prescribe gabapentin.   
 
Figure 24 Frequency Distribution Of Physicians Who’s Decision To Prescribe Gabapentin Would 
Be Influenced By Patient Co-Treatment With Opioids
Impact of Gabapentin Becoming a Controlled Substance
The majority of physicians agreed that gabapentin becoming a controlled sub-
stance would affect their prescribing practices of the medication.  The one Family 
Physician that chose “other” wrote “it would likely affect the ability of some pa-
tients to get their medication.”  In other words, gabapentin becoming a controlled 
substance would affect the prescribing practices of ten out of 16 Family Medicine 
physicians, ten out of eleven Psychiatrists, the Addiction Medicine specialist, the 
Rheumatologist, the Pulmonologist, and the Adult Neurologist.  It would not affect 
the prescribing practices of the Surgeon, who does not practice in the US, the 
Pediatrician, the Occupational Medicine physician, and the Pediatric Neurologist.  
Of the two Family Medicine physicians who commented on their decision, one 
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mentioned that this leads to additional administrative tasks—a signed controlled 
substance contract, a six-month limit on the medication, and paper scripts.  An-
other wrote “Controlled substances are monitored aggressively, sometimes to a 
ridiculous degree.  It would jeopardize my ability to prescribe if I am seen in any 
way as an over prescriber.” 
Of the two Psychiatrists that commented on their decision, one wrote that he or 
she would avoid prescribing gabapentin, if possible, as he or she is averse to 
prescribing controlled medications.   The other Psychiatrist wrote that he or she 
would use it more sparingly, but would protest the decision to the state board be-
cause the Psychiatrist did not think it is appropriate to consider gabapentin a con-
trolled substance.  The Neurologist whose prescribing practices would be unaf-
fected by the decision to make gabapentin a controlled substance wrote that 
most epilepsy medications are already controlled substances.  Therefore, adding 
gabapentin to the list would not be a barrier since the essential support with ad-
ministrative tasks is already in place.  
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  Fig-
ure 25 Frequency Distribution Of Physicians Who’s Decision To Prescribe Gabapentin Would Be 
Influenced By Controlled Substance Status Of The Medication
If gabapentin became a controlled substance, 

















Experience of Emergency Medicine Physicians with Gabapentin
In the past three months, the Emergency Medicine physicians that answered the 
survey saw between five and 50 patients for an overdose or intoxication (Figure 
26). Emergency Medicine physician D did not give a 
number but wrote that about one percent of his or her 
patients came in for an overdose in the past three 
months.  Physician E and H also gave percentages—
50 and ten patients represent five and one 
percent of their patients, respectively.  There-
fore, we can estimate that Emergency Medi-
cine physician D had about ten patients come in for an 
overdose or intoxication in the last three months.  
Benzodiazepines were the most common substances reported by Emergency 
Medicine physicians to be positive on urine toxicology, followed by opioids and 
cannabinoids (Figure 27).  If oxycodone and methadone are grouped with the 
opioids, then the three together are the most common substance reported to be 
positive on urine toxicology.   Five Emergency Medicine physicians reported hav-
ing a patient with a positive urine toxicology screen for ethanol, three reported 
cocaine and amphetamines, and one Emergency Medicine physician each report 
lithium, acetaminophen, and barbiturates.  
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How many of your patients have come in for an 
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Figure 26 Frequency Distribution of Number of 
Patients Treated By An Emergency Medicine 
Physician For An Overdose or Intoxication in a 3-
Month Period 
 
Figure 27 Frequency Distribution of Emergency Medicine Physicians Reporting Positive Result of 
Substance on Urine Toxicology
Of the patients seen for an overdose or intoxication, Emergency Medicine physi-
cians reported that between zero and 80% of their patients were on gabapentin 
(Figure 28).  This includes patients that reported being prescribed gabapentin 
and patients that were not prescribed gabapentin but reported to have taken the 
medication.  The majority of Emergency Medicine physicians reported 0-5% of 
patients seen for an overdose or intoxication were on gabapentin, with Emer-
gency Medicine physician I, who reported 80%, being an outlier. 
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Figure 28 Percentage of Overdose or Intoxication Patients taking Gabapentin
Of the patients seen for an overdose or intoxication, what percentage of patients 
























% of patients seen for an overdose or intoxication that are taking gabapentin









The number of patients prescribed and “on” gabapentin that presented for an 
overdose is very similar (Figures 29 and 30).  Emergency Medicine physician G 
did not report the number of overdose or intoxicated patients on gabapentin but 
reports one percent of them were prescribed gabapentin.  Emergency Medicine 
physician A, who reported none of his or her patients being on gabapentin re-
ported that 20% were prescribed gabapentin.  Emergency Medicine physician I 
reported 80% of patients were on gabapentin and 90% were prescribed 
gabapentin. 
 
Figure 29 Percentage of Overdose or Intoxication Patients Prescribed Gabapentin
 
Figure 30 Percentage of Overdose or Intoxication Patients Prescribed Versus On Gabapentin
Of the patients seen for an overdose or intoxication, what percentage of patients 
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Finally, the Emergency Medicine physicians were asked whether, based on their 
experience, they believed gabapentin was leading to increased overdoses and/or 
intoxications (Figure 31).  Six Emergency Medicine physicians felt that 
gabapentin was not leading to increased overdoses and/or intoxications while 
three felt that it was.  Of the three that felt that gabapentin was leading to in-
creased overdoses/intoxications, one of the Emergency Medicine physicians just 
finished a rotation at the New Jersey poison control center where they were see-
ing an increase in the number of gabapentin overdoses.  
Emergency Medicine physician I, who also responded “yes”, may have misread 
the question because the physician added a comment about elderly patients ac-
cidentally taking benzodiazepines than prescribed.  Of the six Emergency Medi-
cine physicians who did not feel that gabapentin was leading to increased over-
doses/intoxications, Emergency Medicine physician G wrote “Not in our popula-
tion. Our primary care doctors are pretty good about slow titration and monitoring 
of gabapentin prescriptions, primarily for chronic pain.” 
 
Figure 31 Frequency Distribution of Emergency Medicine Physicians That Think Gabapentin is 
leading to Increased Overdoses And/or Intoxications
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DISCUSSION
The purpose of this study was to determine the various real-life off-label prescrib-
ing practices of gabapentin and physicians’ perspectives with regard to particular 
advantages over other drugs and interventions.  In addition, a secondary objec-
tive was to determine physicians’ perspectives regarding whether gabapentin is 
being misused and whether making gabapentin a controlled medication will ad-
versely affect prescribing patterns and patient care.   
Sample Description
There were a total of 50 study participants who responded to the Qualtrics sur-
vey, with the majority being Family Medicine physicians (17 physicians, 34% of 
total participants), Psychiatrists (12 physicians, 24% of total participants), and 
Emergency Medicine physicians (9 physicians, 18% of total participants; Table 1).  
All but one of the Internists and the Intensivist prescribed gabapentin (Table 2).  
Intensivists are less likely to prescribe the medication given the acute setting of 
their practice, similar to Emergency Medicine physicians.
The majority of physicians reported that a small proportion of their patients were 
taking gabapentin, with 21 out of 39 physicians reporting that ten percent or less 
of their patients were taking gabapentin, less than one third reporting 11-20% (12 
out of 39), four reporting 21-30%, and one physician, each, reporting 31-40% and 
41-50% of their patients were taking the medication (Figure 3). This shows that 
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although gabapentin has several indications, it is still being prescribed sparingly 
among the majority of physicians in this study.
The Surgeon had the highest proportion of patients on the medication (41-50%), 
followed by Family Medicine physicians and then Psychiatrists (Figure 4). The 
Addiction Medicine physician wrote that prior to gabapentin becoming a sched-
uled medication, 50-60% of his or her patients were on the medication.  Now it is 
between 0-10 percent. Given that only one Surgeon filled out the survey and that 
this Surgeon chose both “0-10%” and “41-50%,” it is possible that one of the cat-
egories was picked accidentally.  About half of the physicians with patients on 
gabapentin initiated the medication (Figure 5), with Psychiatrists placing a higher 
proportion of their patients on gabapentin than other physicians, followed by 
Family Medicine physicians.  Psychiatrists and Family Medicine physicians use 
gabapentin more frequently than other physicians likely because of the diag-
noses they treat.  Psychiatrists in the study mentioned that most of the other 
medications available to their patients are more addictive (such as benzodi-
azepines) and/or have more side effects and interactions (Appendix C).  
Gabapentin may be a safer alternative, especially for potentially suicidal patients 
[58, 63].  When gabapentin is prescribed appropriately, there is very little to any 
evidence of harm (Appendix C) [58, 63]. Between 2000-2001, 4,837 gabapentin-
only exposures were reported to the American Association of Poison Control 
Centers (AAPCC) Toxic Exposure Surveillance System.  Of these, no medical 
adverse effects were seen in 1,353 individuals, minor effects were seen in 913, 
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moderate effects in 279, major effects in 25, and deaths were reported in three 
people.  Doses associated with the three fatalities were 16.5 g, 48 g, and 59.4 g 
(about a 15-, 45- and 60-day dose, respectively) [63].  In that same year, there 
were 1,298 overdose death due to benzodiazepines, which steadily increased to 
8,791 deaths in 2015 [69].  Similarly, ingestion of antidepressants were involved 
in 28% of suicidal ingestions reported to poison centers in the United States be-
tween 2000 and 2004– 84,670 involved ingestion of a single agent antidepres-
sant.  Of the single agent ingestions, 14.5% involved sertraline, 10% involved 
amitriptyline, bupropion was involved in 9.2%, fluoxetine in 8.5%, venlafaxine in 
6.7%, and citalopram in 6.3%.  Of the 8,316 amitriptyline overdoses, 54.2% of 
the required admission to the critical care unit, 1,220 patients suffered a major 
outcome , and 61 were fatal.  Of the 5,510 venlafaxine-only overdoses, 21.8% of 3
them required admission to the critical care unit, 136 patients suffered a major 
outcome, and 12 were fatal.  Of the 36 duloxetine-only overdoses, 22.2% of the 
required admission to the critical care unit, but luckily none suffered a major out-
come or died [70].
   
 A major outcomes was defined as life-threatening signs or symptoms or significant 3
residual disability secondary to the exposure.
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Conditions For Which Gabapentin is Prescribed
Neuropathic pain was the most common indication for prescribing gabapentin, 
followed by diabetic neuropathy, fibromyalgia and postherpetic neuralgia (Ap-
pendix B).  This is not surprising as these are all FDA approved indications for 
gabapentinoids.  Alcohol dependence or withdrawal and anxiety disorders were 
the most common indication for which the FDA has yet to approve a gabapenti-
noid, followed by insomnia.  Psychiatrists most commonly prescribed gabapentin 
for anxiety disorders (83%), followed by for insomnia (67%; Table 5).  Gabapentin 
is the drug of choice for one of the Psychiatrists for insomnia in a patient with al-
coholism; otherwise it is used second-line for insomnia.  Another Psychiatrist 
prescribes gabapentin second-line for anxiety in patients that did not respond to 
SSRIs, in order to avoid the use of a benzodiazepine. The Psychiatrist also pre-
scribes gabapentin in patients developing anxiety secondary to cannabis use 
discontinuation.  It is not surprising that Psychiatrists were prescribing 
gabapentin to treat anxiety given the addictive potential of anxiolytics, especially 
benzodiazepines, compared to gabapentin.  Also, the risk of harm with overdose 
on gabapentin, compared to benzodiazepines, is small [58].   
Interestingly, neither of the Neurologists prescribed gabapentin for partial 
seizures, although one Family Medicine physician and pediatrician had.  Again, 
only two Neurologists participated in the survey, as compared to seventeen Fami-
ly Medicine physicians.  This finding is likely related to random chance.  
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Overall Benefits of Gabapentin
Some of the reasons for prescribing gabapentin included that the medication had 
the potential to help with more than one indication, it is generic, well-tolerated, 
safe, inexpensive, great response was seen in the past, has few side effects, not 
metabolized in the liver, the benefits outweigh the risks with respect to pain relief, 
moderate evidence of efficacy from patient studies, failure to respond to non-con-
trolled medications and/or all other medications and modalities.  Several physi-
cians have mentioned that gabapentin is less addictive than other medications 
prescribed for the same indication. 
Influence of Substance Use Disorder, Opioid Use Disorder, and Opi-
oid Prescription of Physician Prescribing of Gabapentin
Most of the Psychiatrists would be more likely to prescribe gabapentin to a pa-
tient with a history of Substance Use Disorder (SUD), whereas most of the Fami-
ly Medicine physicians would be less likely (Figure 22).  Most of the Family Medi-
cine physicians that responded to the survey practice in Kentucky, where there is 
a greater fear of gabapentin being combined with heroin or other opioids than 
other parts of the country.  Psychiatrists that responded to the survey were scat-
tered throughout the eastern half of the United States.  Psychiatrists were more 
likely to prescribe gabapentin to patients with SUD given its therapeutic effects in 
patients with alcohol dependence and as a substitute for benzodiazepines and 
opioids.  The same trends and comments were made with respect to OUD and in 
patients prescribed opioids (Figures 23 and 24).  
 65
The patient population, the indication, and alternative treatment options influence 
the decisions among the different specialties. 
Impact of Gabapentin Becoming a Controlled Substance
The majority of physicians agreed that gabapentin becoming a controlled sub-
stance would affect their prescribing practices of the medication (Figure 25).  
Specifically, gabapentin becoming a controlled substance would affect the pre-
scribing practices of 63% of Family Medicine physicians, 91% Psychiatrists, the 
Addiction Medicine specialist, the Rheumatologist, the Pulmonologist, and the 
Adult Neurologist.  It would not affect the prescribing practices of the Surgeon, 
who does not practice in the US, the Pediatrician, the Occupational Medicine 
physician, and the Pediatric Neurologist.  Physicians participating in the survey 
justified their response by mentioning that gabapentin becoming a controlled 
medication will lead to additional administrative tasks—a signed controlled sub-
stance contract, a six-month limit on the medication, and a paper script.  Also, 
they feel that their practices are already scrutinized and their ability to practice 
medicine may be in jeopardy if their prescribing data ever falls outside of the 
normal range, regardless of the legitimacy of their reasons.  
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Experience of Emergency Medicine Physicians with Gabapentin
In the past 3 months, the Emergency Medicine physicians that answered the sur-
vey saw between 5 and 50 patients for an overdose or intoxication (Figure 26). 
Benzodiazepines were the most common substances reported by Emergency 
Medicine physicians to be positive on urine toxicology, followed by opioids and 
cannabinoids (Figure 27).
Of the patients seen for an overdose or intoxication, the majority of Emergency 
Medicine physicians reported that between 0 and 20% of their patients were on 
gabapentin (Figure 28).  The significance of finding that 0- 20% of patients seen 
for an overdose or intoxication reported to be taking or prescribed gabapentin 
depends on the prevalence of gabapentin prescriptions.  From Figure 4 we know 
that, at least in the population surveyed, 0- 40% of patients were prescribed 
gabapentin, with the distribution heavily skewed to the right.  If 20% of overdose 
patients had gabapentin in their system and the prevalence of gabapentin pre-
scriptions was 10%, this finding may be significant and it would be important to 
explore what separates patients more likely to misuse gabapentin from those 
who do not misuse gabapentin. On the other hand, if 10% of overdose patients 
had gabapentin in their system and the prevalence of gabapentin prescriptions 
was 10%, this may be an incidental finding. 
Finally, Emergency Medicine physicians were asked whether, based on their ex-
perience, they felt that gabapentin was leading to increased overdoses and/or 
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intoxications (Figure 31).  Six Emergency Medicine physicians felt that 
gabapentin was not leading to increased overdoses and/or intoxications while 
three felt that it was.  Of the three that felt that gabapentin was leading to in-
creased overdoses/intoxications, one of the EM physicians had just finished a 
rotation at the New Jersey poison control center where they were seeing an in-
crease in the number of gabapentin overdoses.  EM physician I, who also re-
sponded “yes”, may have misread the question because the physician had added 
a comment about elderly patients accidentally taking more benzodiazepines than 
prescribed.  Of course, the sample size of Emergency Medicine physicians sur-
veyed was small so it is difficult to draw any conclusions based on their respons-
es.  Someone who just spent the last month responding to all overdoses in a 
state is likely to believe all substances are more dangerous than they previously 
believed.  Emergency Medicine physicians, on the other hand, who continue to 
remain in the same setting for decades are better equipped to notice trends.  
Although no information was gathered regarding geographic location, there is a 
good chance that most, if not all of the Emergency Medicine physicians practiced 
on the East Coast, primarily in New Jersey, New York and Florida.  The age-ad-
justed deaths due to opioid overdose in 2016 were 18.0, 23.2, and 23.7 per 
100,000 people in New Jersey, New York and Florida, respectively.  In Kentucky, 
the age-adjusted deaths due to opioid overdose in 2016 was 33.5 per 100,000 
people [71].  Although this does not offer any information regarding Emergency 
Department visits, it can be inferred that the Emergency Medicine physicians are 
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working in states where the prevalence of OUD is less than in Kentucky.  There-
fore, the prevalence of misusing gabapentin together with opioids is likely lower 
in the states where the Emergency Medicine physicians surveyed work.    
Limitations
The physicians’ and healthcare facilities’ characteristics such as the geographical 
location, type of facility (public or private), patients’ health seeking behavior and 
perceived needs may influence the physicians’ prescribing behaviors under-
scored in this analysis.  A related limitation is that the sample size was small and 
a convenience sample was used, limiting generalizability.  To allow the physicians 
to freely express their opinions and off-label practices, it was important to limit the 
number of questions asked that might reveal their identity. The number of ques-
tions asked was also limited as much as possible to increase the number of re-
spondents. 
Another limitation of any voluntary survey is responder bias.  Responders with a 
particular view of making gabapentin a scheduled medication, or any particular 
view of gabapentin, were more likely to participate in the survey.  There are two 
competing views physicians can have with respect to gabapentin—that it is a 
dangerous medication and needs to be monitored or that it is a safe medication 
and making it a scheduled medication would limit its use.  Therefore, in a sense, 
the two biases cancel each other out.  Also, part of the purpose of the survey was 
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to hear from physicians who have a particular view of the medication.  Even if 
only a small portion of patients will be less likely to be prescribed gabapentin, if 
these patients would have benefited from it and are not likely to divert or misuse 
it, making gabapentin a controlled substance would negatively impact patient 
care.  The purpose of the study was not to attempt to quantify the degree to 
which prescribing practices will be affected since the small sample size and con-
venience sampling would make such estimate unreliable.  Rather, the purpose of 
the study was to determine if prescribing practices would be affected.  The re-
sults of the survey suggest that they would be affected.  
Limitations of Specific Questions
With respect to hot-flashes, the survey question asked specifically about cancer-
related hot flashes.  More physicians may have prescribed gabapentin for 
menopause-related hot flashes, but only one Family Medicine physician had writ-
ten it in.  In addition, OB/GYNs are more likely to have prescribed gabapentin for 
hot flashes given the results of the studies performed by their organization, the 
American College of Obstetrics and Gynecology (ACOG).  The absence of sur-
vey respondents that are OB/GYNs likely led to fewer physicians reporting use of 
gabapentin for hot flashes and is a limitation of this study.  The same can be said 
about the scarcity of Surgeons participating in the survey and thus the number of 
physicians prescribing gabapentin for post-operative pain.  
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Physicians’ interpretation of “Substance Use Disorder” may have varied accord-
ing to geographic location.  In areas were alcoholism is more prevalent, physi-
cians may have interpreted SUD to be primarily alcoholism and would be more 
likely to prescribe gabapentin for SUD, whereas in areas where OUD is more 
prevalent and alcoholism is less common, physicians may have interpreted the 
SUD to be primarily OUD, which may have affected their response.  For this rea-
son, physicians who responded that they would be more likely to prescribe 
gabapentin to a patient with SUD were asked a followup question— how would a 
history of OUD affect their prescribing practices?  
Unfortunately, routine toxicology screens in the Emergency Department do not 
include gabapentin, fentanyl, and fentanyl analogues.  Therefore, it is difficult to 
determine how often these overdoses are seen in the Emergency Department.  
Having said this, patients overdosing on opioids laced with fentanyl will require 
more naloxone than patients overdosing on just fentanyl alone.  
With respect to patients presenting to the Emergency Department for an over-
dose or intoxication that were taking gabapentin, Emergency Medicine physician 
I may have misunderstood the question because he or she commented that most 
of his or her patients are old and use benzodiazepines almost daily.  Therefore, 




On average 115 Americans die after overdosing on opioids every day [72]. Opioid 
dependence and misuse is a grave national problem that affects multiple aspects 
of public health.  The total national economic burden of prescription opioid 
misuse, including the costs of healthcare, substance use treatment, lost 
productivity, and criminal justice is estimated to be $78.5 billion annually [73].  
Gabapentin may be a contributing partner to this crisis, despite all of its favorable 
medical effects.  Here are my hypotheses. First, Gabapentin alone has less 
severe side effects and is useful for multiple disorders. This is likely why many 
physicians use it off-label and explains the positive opinions represented by the 
physicians in the survey.  

My second hypothesis is that gabapentin potentiates the impact of opioids. This 
explains why a lower dose of opioids are needed to treat pain when the two 
medications are used together and also explains the street appeal of the 
medication when combined with heroin.  
This leads to three recommendations.
Recommendations
1. To ensure current laws and regulation protect health and ensure safety, it 
would be important to conduct further research on the pharmacological effects 
of gabapentin alone and in combination of opioids, especially at higher doses. 
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This will help to implicate gabapentin as a causative factor in opioid overdose 
deaths as opposed to a mere correlation.  
2. Population-based studies should be done examining outcomes with respect to 
morbidity and mortality in patients on both opioids and gabapentin versus 
gabapentin alone, controlling for confounders, such as fentanyl. 
3.  Physicians should be educated about the possible potentiating effect of 
gabapentin when used with opioids and the risk of diversion.  Physicians in 
states where OUD is prevalent are aware of this risk.  However, physicians in 
states where OUD is not as prevalent may not yet be aware of this risk.  There-
fore, it would be important for the public health community to spread this 
knowledge to physicians throughout the country.
Conclusions
Medicine is full of difficult decisions and nuances.  From the results presented 
above, it appears that gabapentin is often either used as a last resort or in pa-
tients with dual/multiple diagnoses. Physicians consider a host of factors in order 
to come up with an appropriate plan of action for a patient.  It is important that the 
public health world make the clinical world aware of new trends such as an in-
crease in opioid overdose deaths among patients taking gabapentin.  However, it 
is equally important that the additional administrative burden on physicians asso-
ciated with the new restrictions on gabapentin not outweigh the benefits to public 
health or take time away from patient care.    
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It is too early to determine how making gabapentin a scheduled medication in 
Kentucky affected clinical practice and opioid overdose deaths, but from the lim-
ited data gathered in this study, it appears that clinical practice will be affected.  
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Have you ever prescribed gabapentin for a patient?
o Yes
o No
o Comments and/or clarification ______________________________________________











o Comments and/or clarification ______________________________________________
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Of your patients that are taking (prescribed) gabapentin, what percentage did you start on 











o Comments and/or clarification ______________________________________________
For which of the following clinical indications have you prescribed gabapentin?  (Feel free to write 
in any comments in the text box).
o Partial Seizures
o Postherpetic Neuralgia




o Tremors in multiple sclerosis
o Cancer-related hot flashes
o Amyotrophic Lateral Sclerosis
o Anxiety disorders
o Bipolar disorder
o Alcohol dependence or with-
drawal
o Brachioradial pruritus





o Neuropathic Pain  
o Other ________________________________________________
o Comments and/or clarification ___________________________________________
What other medication(s) and/or interventions did you try in your patient(s) for before/in addition 
to prescribing gabapentin?  In the comment box, please describe your experience with using 
gabapentin for this indication.  Is there a particular patient profile that appears to respond better to 
gabapentin?  Any other notable factors that you consider?
o Pramipexole
o Ropinirole




o Comments and/or clarification ______________________________________________
What other medication(s) and interventions did you try in your patient(s) for cocaine withdrawal 
before or in addition to prescribing gabapentin?   In the comment box, please describe your expe-
rience with using gabapentin for this indication.  Is there a particular patient profile that appears to 
respond better to gabapentin?  Any other notable factors that you consider? 
o None
o Other ________________________________________________
o Comments and/or clarification _____________________________________________
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What other medication(s) and/or interventions did you try in your patient(s) for before prescribing 
gabapentin?  In the comment box, please describe your experience with using gabapentin for this 
indication.  Is there a particular patient profile that appears to respond better to gabapentin?  Any 



















o Comments and/or clarification 
___________________________________________ 
What other medication(s) and/or interventions did you try in your patient(s) for Diabetic Neuropa-
thy before prescribing gabapentin?  In the comment box, please describe your experience with 
using gabapentin for this indication.  Is there a particular patient profile that appears to respond 














o Isosorbide dinitrate topical spray











o Comments and/or clarification ______________________________________________ 
What other medication(s) /intervention(s) did you try in your patient(s) for tremors related to multi-
ple sclerosis before/in addition to prescribing gabapentin? In the comment box, please describe 
your experience with using gabapentin for this indication.  Is there a particular patient profile that 
appears to respond better to gabapentin?  Any other notable factors that you consider?
o Deep Brain Stimulation
o None
o Other ________________________________________________
o Comments and/or clarification ______________________________________________
What other medication(s) /intervention(s) did you try in your patient(s) for cancer-related hot 
flashes before/in addition to prescribing gabapentin? In the comment box, please describe your 
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experience with using gabapentin for this indication.  Is there a particular patient profile that ap-










o Comments and/or clarification ______________________________________________
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What other medication(s) /intervention(s) did you try in your patient(s) for ALS before/in addition 
to prescribing gabapentin (either for symptom-relief or potential disease modifying treatment)?   In 
the comment box, please describe your experience with using gabapentin for this indication.  Is 
there a particular patient profile that appears to respond better to gabapentin?  Any other notable 


































o Comments and/or clarification ______________________________________________
What other medication(s) /intervention(s) did you try in your patient(s) for anxiety before/in addi-
tion to prescribing gabapentin?   In the comment box, please describe your experience with using 
gabapentin for this indication.  Is there a particular patient profile that appears to respond better to 





























o Comments and/or clarification 
______________________________________________ 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What other medication(s) /intervention(s) did you try in your patient(s) for bipolar disorder before/
in addition to prescribing gabapentin? In the comment box, please describe your experience with 
using gabapentin for this indication.  Is there a particular patient profile that appears to respond 























o Comments and/or clarification ______________________________________________
What other medication(s) /intervention(s) did you try in your patient(s) for alcohol withdrawal or 
dependence before/in addition to prescribing gabapentin?   In the comment box, please describe 
your experience with using gabapentin for this indication.  Is there a particular patient profile that 

















o Comments and/or clarification ______________________________________________
What other medication(s) and/or interventions did you try in your patient(s) for Brachioradial pruri-
tus before/in addition to prescribing gabapentin?  In the comment box, please describe your ex-
perience with using gabapentin for this indication.  Is there a particular patient profile that appears 
to respond better to gabapentin?  Any other notable factors that you consider? 
o Topical capsaicin 0.025% cream










o Comments and/or clarification ______________________________________________
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What other medication(s) and/or interventions did you try in your patient(s) for chronic cough be-
fore/in addition to prescribing gabapentin?  In the comment box, please describe your experience 
with using gabapentin for this indication.  Is there a particular patient profile that appears to re-









o Intranasal ipratropium bromide
o Intranasal glucocorticoid
o Inhaled budesonide











o Cough suppression techniques
o None
o Other ________________________________________________
o Comments and/or clarification ______________________________________________
What other medication(s) and/or interventions did you try in your patient(s) for Fibromyalgia be-
fore/in addition to prescribing gabapentin?  In the comment box, please describe your experience 
with using gabapentin for this indication.  Is there a particular patient profile that appears to re-















o Comments and/or clarification ___________________________________________
What other medication(s) and/or interventions did you try in your patient(s) for hiccups before/in 
addition to prescribing gabapentin?    In the comment box, please describe your experience with 
using gabapentin for this indication.  Is there a particular patient profile that appears to respond 
better to gabapentin?  Any other notable factors that you consider?  















o 2% lidocaine solution
o Acupuncture
o Hypnosis
o Phrenic nerve block
o Implantable vagus nerve stimulator
o None
o Other ________________________________________________
o Comments and/or clarification ___________________________________________ 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What other medication(s) and/or interventions did you try in your patient(s) for postoperative pain 
before/in addition to prescribing gabapentin?  In the comment box, please describe your experi-
ence with using gabapentin for this indication.  Is there a particular patient profile that appears to 




























o Comments and/or clarification ___________________________________________
What other medication(s) and/or interventions did you try in your patient(s) for uremic pruritus 
before/in addition to prescribing gabapentin?  In the comment box, please describe your experi-
ence with using gabapentin for this indication.  Is there a particular patient profile that appears to 
respond better to gabapentin?  Any other notable factors that you consider? 
o Increasing dose of dialysis



















o Omega-3 fatty acid












o Comments and/or clarification ________________________________________
 89
What other medication(s) and/or interventions did you try in your patient(s) for Neuropathic 
pain before/in addition to prescribing gabapentin?  In the comment box, please describe your ex-
perience with using gabapentin for this indication.  Is there a particular patient profile that appears 





















o Comments and/or clarification __________________________________________
What other medication(s) and/or interventions did you try in your patient(s) for this indication be-
fore/in addition to prescribing gabapentin (please specify the indication)?  In the comment box, 
please describe your experience with using gabapentin for this indication.  Is there a particular 
patient profile that appears to respond better to gabapentin?  Any other notable factors that you 
consider? 
o Other medications/interventions tried _________________________________
o Comments and/or clarification _______________________________________
Why did you choose to prescribe gabapentin for this (these) indication(s)?
o Rationale ________________________________________________
Have you successfully weaned any patients off of gabapentin?
o Yes
o No
o Comments and/or clarification ___________________________________________
Why were they weaned off of gabapentin?
o Reason ________________________________________________
If a patient had a history of substance use disorder, would it influence your decision to prescribe 
gabapentin?   If so, what substances would influence your decision?
o Yes, I would be MORE likely to prescribe gabapentin
o Yes, I would be LESS likely to prescribe gabapentin
o No to both
o Other ________________________________________________
o Comments and/or clarification ___________________________________________
If a patient had a history of opioid use disorder, would it influence your decision to prescribe 
gabapentin? 
o Yes, I would be MORE likely to prescribe gabapentin
o Yes, I would be LESS likely to prescribe gabapentin
o No to both
o Other ________________________________________________
o Comments and/or clarification ______________________________________________
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If one of your patients were taking opioids, would it influence your decision to prescribe 
gabapentin?
o Yes, I would be MORE likely to prescribe gabapentin
o Yes, I would be LESS likely to prescribe gabapentin
o No
o Other ________________________________________________
o Comments and/or clarification ___________________________________________
If gabapentin became a controlled substance, would it affect your prescribing practices of the 
medication? (For physicians in Kentucky, has gabapentin becoming a controlled substance last 




o Comments and/or clarification ___________________________________________
How many of your patients have come in for an overdose or intoxication in the past 3 months?  (If 
it's easier, type in the percentage of your patients that came in for an overdose or intoxication in 
the past 3 months) 
o Number of patients in the past 3 months: _____________________________________
o Percentage of patients in the past 3 months: ___________________________________














Of the patients seen for an overdose or intoxication, what percentage of patients report being on 
gabapentin?
o Percentage: ________________________________________________
o Comments and/or clarification ___________________________________________
Of the patients seen for an overdose or intoxication, what percentage of patients report being 
prescribed gabapentin?
o Percentage: ________________________________________________
o Comments and/or clarification ___________________________________________
Do you think gabapentin is leading to increased overdoses and/or intoxications?
o Yes
o No

































Cardiomyopathy ? ? <1% ? Rare ? ? ?
Flushing ? ? 3% ? ? ? ? 8% to 
16%
Hypotension ? 2% ? <2% ? ≤2% ≥1% <1%






? <1% <1% <2% Frequency 
not 
defined.
? ≥1% 2% to 
5%











? <1% ? ? 2% ?










Abnormal gait 2% 1% to 
8%

















? <1% Frequency 
not 
defined.
<1% <1% 1% to 
<5%
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? 7% to 
14%



















≤7% ? 10% to 
33%
















Emotional lability children 
4% to 6%

















































<1% ? ? Frequency 
not 
defined.
<1% <1% 1% to 
<5%




































≥1% 1% to 
<5%








Pruritus 1% ≥1% ≥1% <2% Frequency 
not 
defined.
? ≥1% 3% to 
12%












? ? ? 3% 1% to 
<5%













? ? 9% to 
46%











<1% 21% 15% to 
40%
















<1% 4% 5% to 
17%














? 20% 3% to 
13%
GENITOURINARY
Ejaculatory disorder <1% ≤1% 2% ≤10% ? ? 6% ?
Side Effects
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Impotence 2% ≥1% ? 5% Frequency 
not 
defined.





Decreased libido <1% ? 3% 5% Frequency 
not 
defined.
? 1% to 4% <1%










? ≥1% 1% to 
<5%
Weight gain ? 2% to 
14%



































? ? ? <1% 5% 1% to 
<5%
OPHTHALMIC
Visual field loss <1% 13% ? ? ? ?






























Acetate: D C D
Aclidinium: X
Antiplatelet 
Medications C C C
Alcohol C C C D D D C
Alpha-/Beta-
Agonists: D D D
Alpha2-Agonists D C C
Alvimopan D
Amifampridine X C
Amphetamines C C C
Antiemetics (5HT3 







Agents: C C C C
Antacids D
Asunaprevir D D
Azelastine (Nasal): X X X X X
Benznidazole: X
Blonanserin: D D D D D
Bromopride: C X X X X C
Bromperidol: X X X X X
Buprenorphine: D D D C D
Bupropion D D C
Buspirone D
Cannabis: C C C C C C
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Carbamazepine X




































































Droperidol: D D D D D
Eliglustat: D
Eluxadoline X X
Enzalutamide D D D
Escitalopram: D
Fluconazole X












































Linezolid: X X X X D
Lithium D D
Macimorelin X
Magnesium Salts: D C C C C
Mefloquine D D
Methotrimeprazine
: D D D D D
Methylene Blue: X X X X X
Metoclopramide: D D D D C
Metoprolol: D
Mexiletine D





Oxidase Inhibitors: X X X
Nalmefene D
Naltrexone D
Opioid Analgesics: D D D C C C D X



















Oxomemazine: X X X X X
OxyCODONE: D D D D D
Panobinostat: D D
Paraldehyde X X X X X
PARoxetine: D D
Perampanel: D D D D D
Perhexiline: C D C
Pimozide: X















Sodium Oxybate: D D D D D
St John's Wort: D D D D
Stiripentol: D D
Suvorexant: D D D D D
Tamoxifen: D















































































Hepatic impairment Yes Yes Yes Yes Yes Yes
HTN Yes Yes














         
	 	 	 	 	 	 	 	 

         
	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 

         
	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 

	 	 	 	 	 	 	 	 









Withdrawal: Yes Yes Yes Yes Yes Yes Yes Yes
Disease-related Concerns
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